Vittamed is a neurodiagnostics medical device company with offices in Kaunas, Lithuania and Boston, USA. The company has developed a suite of ultrasound-based devices to non-invasively measure the absolute value of intracranial pressure (ICP), real-time cerebral blood flow autoregulation (CA), and intracranial volumetric wave monitoring. The non-invasive diagnostic methods have been clinically tested and proven in leading neuro centers in Europe and the United States.
The primary focus for Vittamed is to closely measure and monitor critical care patients suffering from neurological diseases, post-stroke complications or traumatic brain injuries. ICP and CA are key vital signs in neurological diagnosing and monitoring because of their correlation with treatment algorithms and outcomes in these patients. Current methods for measuring ICP are invasive and require drilling a hole in the skull to insert a sensor (TBI patients) or a lumbar puncture (neurological patients). These procedures are both risky and very expensive. Our non-invasive technology provides a safer, more cost effective way to capture the same clinical information for doctors and is less traumatic for patients.
Remis Bistras, PhD, MBA, CEO and President of Vittamed Corporation (USA)
Remis Bistras has served as a President and CEO of Vittamed Corporation since 2013. He has more than 20 years of experience with Medical Device and Biotechpharma management and new business development. Prior to Vittamed, Remis was the Worldwide Director of Business Development and Licensing for CIBA Vision/Novartis. He also gained strong entrepreneurial experience as the VP of Business Development at EyeGate Pharmaceuticals, a venture backed start up. Remis holds a PhD from Moscow University and earned an MBA from Carnegie-Mellon University in Pittsburgh. He is located in the Boston office of Vittamed Corporation.